| Sanofi-Aventis (Suisse) SA - Caprelsa 300 mg, comprimés pelliculés | | 62341 | | 02 | | Caprelsa 300 mg | | comprimés pelliculés | | L01EX04 | | Vandetanib | | 01.05.2012 | | |
| | Composition | | vandetanibum 300 mg, calcii hydrogenophosphas dihydricus, cellulosum microcristallinum, crospovidonum, povidonum K 29-32, magnesii stearas, pellicule: hypromellosum, macrogolum 300, E 171, pro compresso obducto. | | Packungsbestandteile | | Coated tablets | | | | | Active Agent | Dose |
|---|
| Vandetanibum | 300 mg |
| | BAG: Active Agent | Dose |
|---|
| Vandetanibum | 300 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| Calcium Hydrogen Phosphate Dihydrate | | | | Cellulosum Microcristallinum | | | | Crospovidonum | | | | E 171 | | color. | | Hypromellosum | | pellicule | | Macrogol | 300 | | | Magnesii Stearas | | | | Povidonum K | 29-32 | | | Pro Compresso Obducto | | |
| |
| | Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 002 | 30 Tablet(s) | 4497.43 | 4907.65 | A | SL | No |
|
|
